A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism

Journal of Psychopharmacology

Volumn 24, Issue 1, 2010, Pages 91-98

  Chan, H Y ^a,b,c   Chang, C J ^d,e   Chiang, S C ^a   Chen, J J ^a   Chen, C H ^a   Sun, H J ^a   Hwu, H G ^f   Lai, Mei Shu ^b  

^a TAOYUAN GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

^d CATHAY GENERAL HOSPITAL   (Taiwan)

^e FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

EPS intolerant; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

BENZODIAZEPINE; CHLORPROMAZINE; CLOPENTHIXOL; CLOTIAPINE; FLUPENTIXOL; HALOPERIDOL; LOXAPINE; OLANZAPINE; PIPOTIAZINE; PROPRANOLOL; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; ZOTEPINE;

ADULT; AGED; AKATHISIA; ARTICLE; BLURRED VISION; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DROWSINESS; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; THIRST; WEAKNESS; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSTONIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD;

EID: 76249100309     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108096070     Document Type: Article

References (31)

1. Awad, AG, Voruganti, LN (2004) Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18: 877-893.
2. Casey, DE (1991) Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 4: 109-130.
3. Chouinard, G., Margolese, HC (2005) Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res 76: 247-265.
4. Citrome, L., Volalka, J. (2002) Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry 10: 280-291.
5. Conley, RR, Mahmoud, R. (2001) A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia. Am J Psychiatry 158: 765-774.
6. Correll, CU, Leucht, S., Kane, JM (2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161: 414-425.
7. Costa e Silva, JA, Alvarez, N., Mazzotti, G., Gattaz, WF, Ospina, J., Larach, V., et al. (2001) Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms. J Clin Psychopharmacol 21: 375-381.
8. Davis, JM, Chen, N. (2004) Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 24: 192-208.
9. Dossenbach, M., Arango-Davila, C., Ibarra, HS, Landa, E., Aguilar, J., Caro, O., et al. (2005) Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 66: 1021-1030.
10. Emsley, RA, Oosthuizen, PP, Joubert, AF, Hawkridge, SM, Stein, DJ (1999) Treatment of schizophrenia in low-income countries. Int J Neuropsychopharmacol 2: 321-325.
11. Frackiewicz, EJ, Sramek, JJ, Herrera, JM, Kurtz, NM, Cutler, NR (1997) Ethnicity and antipsychotic response. Ann Pharmacother 31: 1360-1369.
12. Glazer, WM (2000) Extrapyramidal side effects, tardive dyskinseia, and the concept of atypicality. J Clin Psychiatry 61: 16-21.
13. Grohmann, R., Koch, R., Schmidt, LG (1990) Extrapyramidal symptoms in neuroleptic recipients. Agents Actions 29: 71-82.
14. Guy, W. (1976) Clinical Global Impression (CGI). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health. US Dept Health, Education, and Welfare publication (ADM), pp. 76-338.
15. Heck, AH, Haffmans, PM, De Groot, IW, Hoencamp, E. (2000) Risperidone versus holoperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophr Res 46: 97-105.
16. Huttunen, M. (1995) The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol 15: 4-10.
17. Lane, HY, Lin, HN, Hwu, HG, Jann, M., Hu, WH, Chang, WH (1995) Haloperidol plasma concentrations in Taiwanese psychiatric patients. J Formos Med Assoc 94: 671-678.
18. Lane, RF, Blaha, CD, Rivet, JM (1988) Selective inhibition of mesolimbic dopamine release following chronic administration of clozapine. Brain Res 460: 398-401.
19. Lehman, AF, Lieberman, JA, Dixon, LB, McGlashan, TH, Miller, AL, Perkins, DO, et al. (2004) Practice Guideline for the Treatment of Patients with Schizophrenia. Second ed. Am J Psychiatry 161 (Suppl. 2). 1-56.
20. Leucht, S., Barnes, TR, Kissling, W., Engel, RR, Correll, C., Kane, JM (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160: 1209-1222.
21. Lin, KM, Poland, RE, Lau, JK, Rubin, RT (1988) Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 8: 195-201.
22. Liu, CY, Chiu, NY, Wu, CK, Yuan, LM, Hsiao, MC, Liao, O. (2003) Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan. Int Clin Psychopharmacol 18: 49-51.
23. Overall, JE, Gorham, DR (1988) The brief psychiatric rating scale (BPRS). Psychopharmacol Bull 24: 97-99.
24. Richardson, MA, Craig, TJ (1982) The coexistence of parkinsonism-like symptoms and tardive dyskinesia. Am J Psychiatry 139: 341-343.
25. Robinowitz, J., Lichtenberg, P., Kaplan, Z. (2000) Comparison of cost, dosage and clinical preference for risperidone and olanzapine. Schizophr Res 46: 91-96.
26. Sachdev, P. (2004) Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study. Aust N Z J Psychiatry 38: 445-449.
27. Seeman, P., Tallerico, T. (1998) Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 3: 123-134.
28. Sharma, T., Antonova, L. (2003) Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 26: 25-40.
29. Taylor, D., Paton, C., Kerwin, R. (2003) The Maudsley 2003 Prescribing Guidelines. seventh ed. London: The South London and Maudsley NHS trust.
30. Tran, PV, Hamilton, SH, Kuntz, AJ, Potvin, JH, Andersen, SW, Beasley, C., et al. (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia. J Clin Psychopharmacol 17: 408-418.
31. Weiden, PJ, Miller, AL (2001) Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract 7: 41-47.